Jeffrey Joyce CV 11-8-12 - Kansas City University of Medicine and ...

Office AddressVice President, Division of ResearchKansas City University of Medicineand Biosciences1750 Independence Ave.Kansas City, MO 64106-1453Ph: 816-654-7603Jeffrey N. Joyce, Ph.D.Curriculum VitaeHome Office AddressMedical Research Consulting1370 West 47 th StreetKansas City, MOCell: 480-201-3635 Cell Ph: 480-201-3635E-mail: jjoyce@kcumb.eduE-mail: Jeff.Joyce@cox.netPROFILEA high level of executive management and champion of innovation in research in the biomedicaland healthcare fields with a focus on Research Enterprise Development. Embracing Agility: righttools, right size and right skills to make the enterprise agile and successful. Strong analytical,strategic planning and project management skills; high integrity, superb communication skills,and the ability to work effectively with various functions and levels in an organization. Managedlarge organizations and complex development projects in hospital, research institute andacademic environments. Entrepreneurial Leadership: Expertise with academic medicine, clinicaltrials, basic research, research compliance transfer operations and IP licensing. Presentlyleading the research enterprise at KCUMB. Five previous years of direct experience indeveloping a research administration department within an academic medical center. Tenyears previous experience with consortium building (working with researchers and clinicians)and administrative skills as Director of a State-wide Parkinson’s center and AssociateDirector of Sun Health Research Institute. More than 25 years of experience as an academicscientist working in a medical school hospital setting (1986-1995, University PennsylvaniaSchool of Medicine, Philadelphia) and a free-standing medical research institute (1995-2006,Sun Health Research Institute). More than 25 years of consulting for Pharmaceutical companies inCNS drug development and therapeutic target selectionPROFESSIONAL EXPERIENCEPresent: Vice President for Research at Kansas City University of Medicine andBiosciences A private university comprised of a College of Osteopathic Medicine, founded in1916, and a College of Biosciences, Kansas City University of Medicine and Biosciences is theoldest medical school in Kansas City, Mo., and the largest in Missouri. The position has threeareas of responsibility: (1) Administration and management for the Divisions of SponsoredResearch and Clinical Research; (2) Development of strategic alliances and partnershipsbetween KCUMB and academic sites, hospitals, not-for-profit institutes and commercialorganizations related to research activities; (3) Support of activities directed towards developmentof academic research, including education/training in research for medical students, andphysicians at KCUMB The Division of Research is responsible for management of all contractand sponsored research programs, academic and industry partnerships, IRB, IACUC, complianceoperations, policies, audits, and financial oversight of research at KCUMB.

Jeffrey N. Joyce, Ph.D. December 2012• Oversees the development of current and long-term organizational goals and objectives aswell as policies and procedures for KCUMB research operations• Coordinate with local universities, hospitals, and institutions to establish cooperativeagreements to enhance research programs and increase external funding of research• In conjunction with CFO manage financial aspects of research activities, includingbudgets, cash flow projections and financial reports• Develop and implement institutional policies and practices to ensure that MIHS meets allregulatory requirements and assurances for the conduct of sponsored programs (research,grants and contracts) including requirements for managing financial conflicts of interest,investigating scientific misconduct and reviewing human subjects research.• Oversee development of research facilities and common equipment, including planning forresearch infrastructure project development2007 - 2012 Director of the Department of Research, Maricopa Integrated Health SystemMaricopa Integrated Health Service (MIHS) includes the Maricopa Hospital and Medical Centerand eleven Family Health Centers located throughout the Phoenix metropolitan area. As anacademic medical center it is home to 10 residency programs that provide training forapproximately 60% of all physicians in the State of Arizona. The department was developedunder my leadership from 2007 to 2012.Milestones• 2007 Developed two divisions to improve oversight of research activities:-Pharmaceutical Contracts and Compliance, and-Academic Research and IRB AdministrationThis ensured proper management of all contract and sponsored research programs, academicresearch, human subject protection, research policies, audits, and financial oversight ofresearch accounts.• 2008 Worked with Finance Department to put Research Grants Accounting operationsinto place. Research requires separate accounting for each research project and a separategrant accounting system is required to effectively manage and track these cost centers• Worked with Finance Department to develop operational system to “clean” patientaccounts of non-permissible research charges. Aligned with electronic medical recordimplementation.• June 2009 – New indirect cost proposal submitted to DHHS. Substantial increase in costrecovery approved for July 2010. The proposal was developed in cooperation with theDirector of Government Reporting for this institution and Huron Consulting.• 2009- 2010 Memorandum of Understanding for Research and Graduate EducationPartnership between Maricopa Integrated Health System and Arizona State University(ASU, Tempe, AZ) executed. Overarching Technology Transfer agreement betweenMIHS and ASU [Arizona Technology Enterprises] approved to implement for allresearch collaborations and contracts. Human Subject’s Protection (IRB) reciprocityagreement between MIHS and ASU executed. Determines IRB authority over jointresearch programs where clinical research is conducted solely at ASU or MIHS.• Spring 2011 – Led MIHS’s participation in Arizona Biospecimen Consortium andArizona Public Cord Blood Banking Program funded by Arizona Biomedical ResearchCommission2

Jeffrey N. Joyce, Ph.D. December 2012Accomplishments• Number of active research projects (sponsored and resident-related) by 160% in 4 years• Number of initiated Sponsored contracts completed per month increased by 250%• Number of Research projects as part of residency training programs increased 375%• Federal grants increased by more than 200% in four years1995- 2006 Concurrent Positions at Sun Health Research Institute, Sun City AZ1995- 2006 Associate Director, Sun Health Research InstituteEstablished in 1987, it is a not-for-profit Institute within the Sun Health Corporationhealthcare network (merged with Banner Health in 2008). The Institute is focused ontransitional research in the neurodegenerative disorders of the aged, with emphasis inAlzheimer’s Disease, Parkinson’s Disease and Arthritis. Co-managed research anddevelopment for the Institute, facilitated development of grants and contracts, leddevelopment of strategic alliances with pharmaceutical companies. Personally increasedsponsorship from Pharmaceutical and Biotech companies 20-fold from 1995-2000. Directlyinvolved in recruitment of faculty that increased from 3 to 36 during the same 10 years, andstood at 36 Ph.D.s/M.D.s and 36 support staff.1995- 2006 Senior Scientist and Head, Thomas H. Christopher Parkinson's DiseaseResearch CenterInstituted the Center in 1995 with one laboratory, and expanded it to encompass fourlaboratories. Responsible for personnel recruitment, program development, fiscalmanagement, fund procurement. The Center was awarded 11 research grants and contractsduring that period, including four from pharmaceutical companies, three from the Michael J.Fox Foundation for Parkinson’s Disease Research, and three NIH-funded awards.1997- 2004 Head, Arizona Parkinson’s Disease CenterResponsible for strategic development of the consortium in 1997 that officially became theArizona Parkinson’s Disease Center in the year 2000. Led the strategic development andpolitical action committee in 2000 that developed State of Arizona Legislature funding forParkinson’s Disease. Administrative Director from 2000-2004 for 3 clinical sites and 6research laboratories (at two institutes) that constituted the Arizona Parkinson’s DiseaseCenter. Oversaw all aspects of administration: budget, support staff, regulations (IRB), andfund procurement.1995- 2005 Co-Director Parkinson’s Disease Brain Donor Program.In 1995, in collaboration with Dr. Charles Adler (Mayo Clinic- Scottsdale), initiated thedevelopment of an antemortem clinical testing program for the Sun Health ResearchInstitute Brain Donor Program. The program expanded to support neuropathologicalassessment, enrollment of Parkinson’s Disease subjected and ultimately a clinical researchprogram with Parkinson’s cases. Dr. Joyce developed internal and external funding for theprogram from 1998-2004. The Arizona Parkinson’s Disease Center is now headed by Dr.Adler, with Dr. Thomas Beach as head of the pathology services component.3

Jeffrey N. Joyce, Ph.D. December 20121995- present Pharmaceutical Consultant, CNS Drug Discovery and Target DevelopmentConsultant to UpJohn Pharmacia and Pharmacia Corporation for 6 years in anti-Parkinsonian drug development before company was acquired by Pfizer. Consultant toInstitute de Recherchés Servier (Suresnes, France) for five years for antipsychotic andanti-Parkinsonian drug development. Consultant to Pfizer Pharmaceuticals, Eli Lilly andCompany, Schwarz Biosciences, Forest Laboratories, Gedeon Richter Plc.1986-1995 Positions at University of Pennsylvania School of Medicine, PhiladelphiaPA1989-1995 Associate Professor of Psychology and Neuroscience in Psychiatry andDirector of the Laboratory of Molecular Neurochemistry, University ofPennsylvania School of Medicine, Philadelphia PAFaculty Member: School of Medicine in the Department of Psychiatry, CRBPsychiatry Research, directed research programs in developmental neurobiology and themolecular neurochemistry of the human brain, particularly related to neuropsychiatric andneurodegenerative illnesses.Responsibilities included research laboratory operations including fiscal management,supervision of 18 scientists, and fund procurement. P.I. in several program project grantsthat crossed departmental boundaries in Pharmacology, Neurosurgery andNeuropathology. Awarded 11 grants including 2 NIH R01 grants.Research Excellence: Awarded the prestigious Ziskind-Somerfeld Research Award forresearch into the biological substrates of schizophrenia by the Society for BiologicalPsychiatry in 1997.1989-1990, Director, Clinical Research Building Psychiatry Research DepartmentFacilitated the consolidation of 9 laboratories spread through the University Campus to oneResearch Building, inaugurating the comprehensive basic research programs of the ResearchDepartment in Psychiatry1986-1989 Research Assistant Professor of Pharmacology, University of PennsylvaniaSchool of Medicine, Philadelphia PAFaculty member of the School of Medicine in the Department of Pharmacology,Associate Member David Mahoney Institute of Neurological Sciences, MemberGraduate Group in Pharmacology, University of Pennsylvania.Responsibilities included teaching graduate courses, laboratory operations includingfiscal management, supervision of 8 staff, and fund procurement. Awarded 5independent grants in three-year period.ADDITIONALEXPERIENCEPROFESSIONAL2010- 2012 Executive Steering Committee for the CONECTR (Community Oriented4

Jeffrey N. Joyce, Ph.D. December 2012Network to Enhance Clinical Trials and Research) an ASU-Quintiles alliance.2009 - 2012 Board Member of Carl T. Hayden Medical Research Foundation (Phoenix, AZ),associated with the Phoenix VA Health Care System2006 -2009 Liason Committee member, American College of Neuropsychopharmacology2001 - 2004 Finance Committee member, American College of Neuropsychopharmacology1995- 2006 Radiation Safety Officer, Sun Health Research Institute2001 - 2006 Flinn Foundation –Battelle Commission Bioindustry Roadmap-NeurosciencePlatform Committee1997 - 2000 Board Member and Finance Committee Chair, Annual Spring BrainConference1994 - 1994 Chair Finance Committee International Behavioral Neuroscience Society1993 - 1993 Program Chair, International Behavioral NeuroscienceMEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIESNational Organization of Research Development Professionals (2010)Health Care Compliance Association (2010)Society of Research Administrators (SRA) International (2009)American College of Healthcare Executives (2008)Public Responsibility in Medicine and Research (2008)Society for Neuroscience (1978)Society for Biological Psychiatry (1989)International Society for Developmental Neuroscience (1989)American Society for Pharmacology and Experimental Therapeutics (1990)American College of Neuropsychopharmacology-Associate Member (1992-1994)-Member (1995)-Fellow (2002)- Liaison Committee member (2005-2009)- Finance Committee member (2001-2004)International Behavioral Neuroscience Society (Charter Member, 1992)-Program Chair (1993)-Chair Finance Committee (1994-1995) -Doubled annual sponsorship support-Fellow (1995)Annual Spring Brain Conference (1995)-Board Member (1997-2000)-Finance Committee Chair (1997-2000) -Quadrupled annual sponsorship supportThe Movement Disorders Society (1996)Collegium Internationale Neuro-Psychopharmacolgicum (2000)European College of Neuropsychopharmacology (2004)5

Jeffrey N. Joyce, Ph.D. December 2012Editorial Board Synapse (1992- 2004)Neuropsychopharmacology (1995- 2000)Neurotoxicity Research (1998-2007)Grant Reviews- Clinical Neuroplasticity and Neurotransmitters [CNNT] study section (2006-2007)- Neurodegeneration and the Biology of the Glia Study Section [NDBG] (2005-2007)- NIA ZAG1 ZIJ-9 (M3) Beeson Career Development- Special Emphasis Panel (2005-2007)- VA Merit Review Subcommittee – Chair, Neurobiology D. (2003-2007)-Department of Defense-Neurotoxin Exposure Program review panel (2002)-Reviewer for American Federation for Aging Research (1999-2003)-Reviewer for Veterans Administration Merit Award (external)-Reviewer for American Health Assistance Foundation (external)-Reviewer for Natural Sciences and Engineering Research Council of Canada (external)-Reviewer for The Wellcome Trust, London, England (external)-Reviewer for Ontario Mental Health Foundation, Canada (external)-Reviewer for NSF grants (external)-Reviewer for NIMH – Ad Hoc to Review Group NPNC (1995-1998)ACADEMIC EXPERIENCE (1986-2011)EDUCATION1983-1986 University of California, Irvine, Department of Psychobiology, NRSA andNINDS Postdoctoral Fellowships1977-1983 University of Florida, Gainesville, Departments of Psychology and ofNeuroscience. Ph.D. awarded 1986 in Physiological Psychology1974-1977 University of Illinois, Champaign-Urbana, IL. B.S. in Psychology/BiologyCognatePostgraduate Training and Fellowship Appointments1983-85 NRSA Postdoctoral Training Grant, Postdoctoral Trainee, Department ofPsychobiology, University of California at Irvine1985-86 NINCDS Postdoctoral Fellowship, Department of Psychobiology, University ofCalifornia at IrvineFACULTY APPOINTMENTS2012 - Professor of Pharmacology, Kansas City University of Medicine and Biosciences2011- 2012 Research Professor of Neurology and Psychiatry University of Arizona Collegeof Medicine - Phoenix2007 – 2012 Adjunct Professor in the School of Biological and Health Systems Engineering,Arizona State University, Tempe, AZ1995- 2006 Senior Scientist and Head, Thomas H. Christopher Parkinson's Disease Research6

Jeffrey N. Joyce, Ph.D. December 2012Center1998- 2007 Adjunct Professor in the Molecular and Cellular Biology Graduate Group,Arizona State University, Tempe, AZ1996- 2007 Adjunct Professor of Psychology, Arizona State University, Tempe, AZ1995-1998 Adjunct Associate Professor of Psychology and Neuroscience in Psychiatry,University of Pennsylvania School of Medicine, Philadelphia, PA1992-1995 Member, Graduate Group in Neuroscience, University of Pennsylvania1989-1995 Research Associate Professor of Psychology and Neuroscience in Psychiatry1989-1995 Research Associate Professor of Pharmacology (Secondary with voting rights)1987-1995 Associate Member David Mahoney Institute of Neurological Sciences1987-1989 Research Assistant Professor of Pharmacology in Psychiatry (Secondary)1986-1995 Member Graduate Group in Pharmacology, University of Pennsylvania1986-1989 Research Assistant Professor of Pharmacology, University of PennsylvaniaACADEMIC COMMITTEES (1986-2006)Academic Committees at the University of Pennsylvania (1986-1994)1986-1994 Member, Faculty Advisory Board on Aging1988-1994 Member, Executive Board, Hartford Foundation Aging Fellowship Program1989-1994 Member, Research Committee in Psychiatry1988-19941991-1992Member, Institute of Neurological Sciences Admission's CommitteeMember, Committee to Review the Department of Microbiology Chair,1992-1994 Graduate Education in Psychiatry SubcommitteeMaior Teaching and Clinical Responsibilities at the Univeristy of Pennsylvania (1986 - 1995):1. Director, Laboratory of Chemical Neuroanatomy2. Course Director, Pharamcology-Psychiatry 550: Neuropsyhopharmacology3. Course Director, Pharmacology 100: Behavioral Pharmacology Laboratory4. Co-Director, Pharmacology 540: Behavioral Neuropharmacology5. Lecturer, Pharmacology 510: Neurochemistry6. Lecturer to Biological Basis of Psychiatric Disorders, BBB-Psychiatry 280Academic Committees at Arizona State University (1997- 2006)Thesis Advisory Committee: Taline Khroyan, Department of PsychologyThesis Advisory Committee: Rita Fuchs, Department of PsychologyCo-Chair Thesis Advisory Committee: Steve Presgraves, Molecular and Cellular BiologyProgram.Member, “Stress Center” Advisory Committee (1999 – 2003)TRAINING AND MENTORING (1986-2006)Postdoctoral Trainees:Bethany Neal-Belliveau, Ph.D., 1987 University of Minnesota1987- 1991 Postdoctoral Trainee (J.N. Joyce, Faculty Supervisor)Support:Training Program in Neuropsycho-pharmacology, Department of Pharmacology,7

Jeffrey N. Joyce, Ph.D. December 2012University of Pennsylvania School of MedicineTourette Syndrome Association (7/1/90 - 6/30/91), Developmental Plasticity of BasalGanglia Dopamine Systems,Total Direct Costs: $25,000National Institute of Mental Health (10/1/90 - 9/30/91), Dopamine Denervation andReceptor Subtype Regulation (F32 MH09888), Total Direct Costs: $28,000Current Postion: Associate Professor of Psychology, Indiana University, Indianapolis, INAngela Murray, Ph.D., 1990 Royal College of Surgeons, Dublin, Ireland1990-1992 Postdoctoral Fellow (J.N. Joyce, Faculty Supervisor)Support:National Parkinson Foundation, Inc. (7/01/91 - 6/30/92), Dopamine Receptors inParkinson's and Alzheimer's Disease, Total Direct Costs: $40,000.Current Postion: Intellecutal Patents Advisor, Dublin, IrelandLise Rioux, Ph.D., 1991 Laval Univeristy, Quebec, Canada1991- 1994 Postdoctoral Fellow (J.N. Joyce, Faculty Supervisor)Support:Fonds De La Recherche En Sante Du Quebec (7/01/91 - 3/30/94), Temporal Correlationof mRNA Coding for dopamine Receptors in Different Striatal Compartments as Relatedto Maturation of Dopamine Afferents, Total Direct Costs: $53,000NIB. (4/01/94 - 3/30/95), Substance P Receptors in Parkinson's and Alzheimer's Disease,Total Direct Costs: $30,000.Current Postion: Investigator, Dept Neurobiol & Anat, Drexel University Medical Center,Philadelphia, PAAdvanced Trainees:Eugenia Gurevich,Ph.D., 1985 Moscow State University, Russia1991-1995 Postdoctoral Fellow (J.N. Joyce, Faculty Supervisor)1995-2001 Scientist, Thomas H. Christopher Center for Parkinson's Disease ResearchCurrent Postion: Associate Professor, Department of Pharmacology, VanderbiltUniversity Medical Center, Nashville, TNInna Kruman, Ph.D., 1983 Moscow State University, Russia2001-2006 Staff Scientist, Thomas H. Christopher Center for Parkinson's DiseaseResearchCurent Position: Associate Professor, Department of Neuropsychiatry, Garrison Instituteon Aging, Texas Tech University Health Sciences CenterThesis Supervision:8

Jeffrey N. Joyce, Ph.D. December 2012Sara Goldsmith: "Limbic dopamine D2 receptors: Interspecies differences and alterations inschizophrenia," presented in fulfillment of Doctor of Philosophy degree, Department ofPsychology, University of Illinois, Chicago, May 1993. (J.N. Joyce, Faculty Supervisor- U Penn)Paul Frohna: "The developmental plasticity of the dopamine systems: Effects of neonatal 6-hydroxydopamine lesions on the ontogenesis of the mesostriatal dopamine neurons and ofstriatal dopamine D1 and D2 receptors and mRNA," Department of Pharmacology, University ofPennsylvania School of Medicine (awarded, 1995).Steve Presgraves: “SHSY-5Y neuroblastoma cells a DA-phenotypic model system for studyingD3 receptor agonist neuroprotection against MPP+-induced cell death” Center for Molecular andCellular Biology, Arizona State University, Tempe AZ (awarded, 2005).T.C. Der, M.S.: “Role of the serotonin system in modulating neurotoxicity of MPTP todopamine neurons”. Graduate Program in Biology, Arizona State University, Tempe AZ(Awarded, 2007).MEDICAL SCIENCE COMMUNICATIONS AND PRESENTRATIONSIn 2007 I moved into the positions with largely administrative responsibilities but remain activein the research community. I have provided over 65 invited lectures at national and internationalmeetings, universities and other public forums in the areas of neuroscience, neuropsychiatry andneurodegenerative disorders. I have published over 110 original papers, reviews and bookchapters on subjects related to the areas of neuroscience, neuropsychiatry andneurodegenerative disorders.PEER-REVIEWED PUBLICATIONS, INVITED REVIEWS, BOOK CHAPTERSBIBLIOGRAPHYIn Research Administration and DevelopmentJoyce, Jeffrey N. Regulatory compliance for research in an academic medical center.Compliance Today [Health Care Compliance Association monthly] Vol 13, No. 12,Pages 29- 37, December 2011.Original Papers1. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alphasynuclein pathology in postmortem Parkinson's disease brains with and withoutdementia.. Exp Neurol. 2010 Sep;225(1):210-82. Massa, S., Yang, T., Xie, Y., Shi, J. Bilgen, M. Joyce, J. Nehama, D. Rajadas, J., andLongo, F. Small Molecule BDNF Mimetics that Activate TrkB Signaling and PreventNeuronal Degeneration. J Clin Invest. 2010 May 3;120(5):1774-85.3. Iarkov, A., Der, T.C., Joyce, J.N. Age-related differences in MK-801 induced behaviorsin D 3 receptor knock out mice. European Journal of Pharmacology, Volume 627, Issues1-3, 10 February 2010, Pages 177-184.4. Yarkov, A., Der, T.C., Joyce, J.N. Locomotor activity induced by MK-801 is enhanced in9

Jeffrey N. Joyce, Ph.D. December 2012dopamine D 3 receptor knock out mice but suppression by dopamine D 3 /D 2 antagonistsdoes not occur through the dopamine D 3 receptor. In Press, European Journal ofPharmacology, Volume 627, Issues 1-3, 10 February 2010, Pages 167-172 .5. Duka, T., Duka,V. Joyce, J.N. and Sidhu, A. Alpha-synuclein induces GSK-3β–catalyzed tau phosphorylation in Parkinson’s Disease models. FASEB J. 2009Sep;23(9):2820-2830.6. Kufah1, P.R. Zavala, A.R., Singh, A., Thiel, K.J., Dickey, E.D., Joyce, J.N.,Neisewander, J.L c-Fos expression associated with reinstatement of cocaine-seekingbehavior by response-contingent conditioned cues. Synapse. 2009 Oct;63(10):823-835.7. Zavala, A.R., Osredkar, T., Joyce, J.N. and Neisewander, J.L. Upregulation of ArcmRNA expression in the prefrontal cortex following cue-induced reinstatement ofextinguished cocaine-seeking behavior. Synapse, 2008 Jun;62(6):421-31.8. Mastroeni D, Grover A, Leonard B, Joyce JN, Coleman PD, Kozik B, Bellinger DL,Rogers J. Microglial responses to dopamine in a cell culture model of Parkinson'sdisease. Neurobiol Aging. 2009 Nov;30(11):1805-179. Lockhart, A., Lamb, J.R., Osredkar, T., Sue, L.I., Joyce, J.N., Ye, L., Libri, V., Leppert,D. and Beach, T.G. PIB is a non-specific imaging marker of amyloid-beta (Abeta)peptide-related cerebral amyloidosis. Brain. 2007 Oct;130(Pt 10):2607-261110. Bychkov ER, Gurevich VV, Joyce JN, Benovic JL, Gurevich EV. Elevated expression ofarrestins and G protein-coupled receptor kinases in the striatum of Parkinson’s patientswith concomitant dementia. Neurobiol Aging. 2008 Mar;29(3):379-96.11. Yoshimoto K, Nishimura A, Hattori H, Joyce JN, Yoshida T, Hioki C, Kogure A, UedaS. In vivo brain microdialysis studies on the striatal dopamine and serotonin release inzitter mutant rats. Mech Ageing Dev. 2006 Jul;127(7):628-3212. Nakadate K, Noda T, Sakakibara SI, Kumamoto K, Matsuura T, Joyce JN, Ueda S.Progressive dopaminergic neurodegeneration of substantia nigra in the zitter mutant rat.Acta Neuropathol (Berl). 2006 Jul;112(1):64-7313. Ueda S, Sakakibara S, Nakadate K, Noda T, Shinoda M, Joyce JN. Degeneration ofdopaminergic neurons in the substantia nigra of zitter mutant rat and protection bychronic intake of Vitamin E. Neurosci Lett. 2005 Jun 3;380(3):252-614. Joyce, J.N., Woolsey, C., Ryoo, H., Borwege, S., Hagner, D. A low dose of pramipexoleis neuroprotective in the MPTP mouse model of Parkinson’s disease, and acts todownregulate the dopamine transporter via the D 3 receptor. BMC Biology 2004, 2:22.15. Presgraves, S., Borwege, S., Millan, M. J. and Joyce, J.N. Neuroprotective effects ofS32504 and pramipexole against 1-methyl-4-phenylpyridinium (MPP+) in terminallydifferentiated SH-SY5Y cells are mediated by the D 3 receptor and BDNF dependentpathways. Experimental Neurology, 190(1):157-170.16. Dluzen, D.E., McDermott, J.L., Anderson, L.I., Kucera, J., Joyce, J.N., Osredkar, T.,Walro, J.M. Age-related changes in nigrostriatal dopaminergic function are accentuated10

Jeffrey N. Joyce, Ph.D. December 2012in +/- brain derived neurotrophic factor mice. Neuroscience, 128:201-208, 2004.17. Presgraves, S., Ahmed, T., Borwege, S. and Joyce, J.N. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamineagonists. Neurotoxicity Research, 5(8):579-598, 2004.18. Neisewander, J.L., Fuchs, R.A., Tran-Nguyen, L.T.L., Weber, S.M., Coffey, G.P. andJoyce, J.N. Abstinence from a cocaine self-administration regimen in rats increasesdopamine D 3 receptor binding: Implications for understanding cocaine-seeking behavior.Neuropsychopharmacology, 29(8):1479-87., 2004.19. Millan, M.J., Di Cara, B., Hill, M., Jackson, M., Joyce, J.N., Brotchie, J., McGuire, S.,Crossman, A., Jenner, P., Gobert, A., Peglion, J.-L. and Brocco, M. S3504, a novelnaphtoxazine agonist at D3/D2 receptors: II. Actions in rodent, primate and cellularmodels of antiparkinsonian activity in comparison to ropinirole. J Pharmacol Exp Ther2004;309 921-935.20. Joyce, J.N. Der, T.C., Renish, L, Osredkar, T., Hagner, D., Reploge, M, Sakakibara, S.,and Ueda, S. Loss of D 3 receptors in the zitter mutant rat is not reversed by L-dopatreatment. Exp. Neurol., 187/1: 178-189, 2004.21. Joyce, J.N., Renish, L. Osredkar, T., Walro, J.M., Kucera, J. and Dluzen, D.E.Methamphetamine induced loss of striatal dopamine innervation in BNDF heterozygotemice does not further alter D 3 receptor concentrations. Synapse, Volume 52, Issue 1(April 2004): 11-19. DOI: 10.1002/syn.10309.22. Beach TG, Walker DG, Sue LI, Newell A, Adler CH, and Joyce J.N. Substantia NigraMarinesco Bodies are associated with decreased striatal expression of dopaminergicmarkers. J Neuropathol Exp Neurol. 2004 Apr; 63(4):329-37.23. Iarkov, A., Hagner, D., Reploge, M., Joyce, J.N. Behavioral effects of dopamine agonistsin MPTP lesioned D 3 receptor knockout mice. Pharmacol Biochem Behav, Vol 76/3-4 pp551-562, 2003 (DOI: 10.1016/j.pbb.2003.09.011).24. Joyce, J.N. Presgraves, S., Renish, L,. Borwege, B., Hagner, D, Osredkar, T, Replogle,M, Paz Soldán, M. M., Millan, M.J. Neuroprotective effects of the novel D3/D2 receptoragonist and anitparkinson agent S32504, in vitro against 1-methyl-4-phenylpyridinium(MPP+)and in vivo against 1-methyl- 4-phenyl-1,2,2,6-tetrahydropyridine (MPTP):acomparison to ropinirole. Exp. Neurol., 184/1 pp. 393-407, 2003. (DOI 10.1016/S0014-4886(03)00353-4).25. Joyce, J.N., H. Ryoo, T. B. Beach, J. N. Caviness, M. Stacy, E. V. Gurevich, M. Reiser,C. H. Adler. Loss of clinical response to levo-dopa in Parkinson’s disease and cooccurrencewith dementia: role of D3 and not D2 receptor. Brain Res. 955:138-152,2002.26. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normalaging, clinically possible Parkinson's disease, and clinically probable Parkinson's disease:longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism andRelated Disorders, 9:103-110, 2002.11

Jeffrey N. Joyce, Ph.D. December 201227. Gurevich, E.V. Robertson, R, and Joyce, J.N. Thalamo-cortical afferents controltransient expression of the dopamine D 3 receptor in the rat somatosensory cortex.Cerebral Cortex 11:691-701 2001.28. Joyce, J.N. D 2 but not D 3 receptors are elevated after 9 or 11 months chronic haloperidoltreatment: influence of withdrawal period, Synapse 40:137-144, 2001.29. Gurevich, E.V. Kordower, J.H., and Joyce, J.N. Ontogeny of dopamine D 2 receptormRNA expressing cells in the human hippocampal formation and temporal cortex. J.Chemical Neuroanatomy, 20:307-325, 2000.30. Gurevich, E.V., Himes, W. and Joyce, J.N. The dopamine D 3 receptor is transientlyexpressed in rat barrel field cortex. J. Comp. Neurol. 420:35-51, 2000.31. Joyce, J N., K. Yoshimoto, and S. Ueda. The zitter rat exhibits reduced D 3 receptornumber with degeneration of the mesostriatal dopamine system. NeuroReport 11:2173-2175, 2000.32. Ma SY, Ciliax BJ, Stebbins G, Jaffar S, Joyce JN, Cochran EJ, Kordower JH, Mash DC,Levey AI, Mufson EJ. Dopamine transporter-immunoreactive neurons decrease with agein the human substantia nigra. J Comp Neurol 409:25-37, 1999.33. Gurevich, E.V., Himes, W., and Joyce, J.N. Developmental regulation of expression ofthe D3 dopamine receptor in rat nucleus accumbens and Islands of Calleja. J PharmacolExp Ther.289: 587-598, 199934. Neal-Beliveau, B.S. and Joyce, J.N.. Timing: A critical determinant of the functionalconsequences of neonatal 6-OHDA lesions. Neurotoxicol Teratol. 2:129-140, 1999.35. Thomas, W.S., Neal-Beliveau, B.S., and Joyce, J.N.. There is a limited critical period fordopamine’s effects on D1 receptor expression in the developing rat neostriatum. Dev.Brain Res. 111: 99-106, 1998.36. Gurevich, E.V., and Joyce, J.N. Distribution of dopamine D 3 receptor expressingneurons in the human forebrain: Comparison with D 2 receptor expressing neurons.Neuropsychopharmacol. 20: 60-80, 1999.37. Joyce, J.N.; Murray, A.M., Hurtig, H.I.., Gottlieb, G.L. and Trojanowski, J.Q Loss ofdopamine D2 receptors in Alzheimer’s disease with Parkinsonism but not Parkinson’s orAlzheimer’s disease. Neuropsychopharmacol. 19:472-480, 199838. Ryoo, H.L, Pierottie, D, and Joyce, J.N. Dopamine D3 receptor is decreased and D2receptor is elevated in the striatum of Parkinson’s Disease. Movement Disorders 13:788-797, 1998.39. Rioux, L., Nissanov, J. and Joyce, J.N. Increased number of [125I]BH-substance Preceptors in schizophrenia. Prog. Neuropsychopharmacol. Biol Psychiatry,22:1295:1299, 1998.40. Neal-Beliveau, B.S. and Joyce, J.N. Behavioral responsitivity to dopamine receptor12

Jeffrey N. Joyce, Ph.D. December 2012agonists after extensive striatal dopamine lesions during development. Develop.Psychobiol., 32:313-326, 1998.41. Gurevich, E.B. J. Kordower, and Joyce, J.N. Dopamine D2 receptor mRNA is expressedin maturing neurons of the human hippocampal and subicular fields. Neuroreport,8:3605-3610, 1997.42. Joyce, J.N. and Myers, A.J, and E. V. Gurevich: D2 receptor bands in normal humantemporal cortex are absent in Alzheimer’s disease. Brain Res. 784: 7-17, 1998.43. Joyce, J.N., Smutzer, G., Whittey,C., Myers, A., and Bannon, M: Differentialmodification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain ofsubjects with Parkinson’s, Alzheimer with Parkinsonism and Alzheimer’s disease.Movement Disorders, 12:855-897, 1997.44. Gurevich, E.V. and Joyce, J.N. Ziskind-Somerfeld Research Award 1997. Alterations inthe cortical serotonergic system in schizophrenia: A postmortem study. Biol Psychiatry42: 529-545, 1997.45. Frohna, P.A., Neal-Beliveau, B.S. and Joyce, J.N. Delayed plasticity of the mesolimbicdopamine system following neonatal 6-OHDA lesions. Synapse 25:293-305, 1997.46. Goldsmith, S., Shapiro, R and Joyce, J.N. Disrupted pattern of dopamine D2 receptor inthe temporal lobe in schizophrenics: a postmortem study. Arch. Gen. Psychiatry, 54:649-658, 1997.47. Gurevich, E.V., Bordelon, Y., Shapiro, R., Arnold, S., Gur, R. and Joyce, J.N. DopamineD 3 receptors and use of antipsychotics in patients with schizophrenia: A postmortemstudy. Arch. Gen. Psychiatry, 54:225-232, 1997.48. Rioux, L., Frohna PA, Joyce JN, Schneider J. The effects of chronic levodopa treatmenton pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonianmonkeys. Movement Disorders 12:148-158,1997.49. Solbrig, M.V., Koob, G.F, Joyce, J.N. and Lipkin, W.I. A neural substrate ofhyperactivity in Borna disease: changes in brain dopamine receptors. Virology 222: 332-338, 199650. Goldsmith, S. and Joyce, J.N. Dopamine D2 receptors are organized in bands in normalhuman temporal cortex. Neuroscience 74:435-451, 1996.51. Gurevich, E.V. and Joyce ,J.N. Comparison of [ 3 H]paroxetine and [ 3 H]cyanomipraminefor quantative measurement of serotonin transporter sites in human brain.Neuropsychopharmacol.14:309-323, 1996.52. Frohna, P.A., Neal-Beliveau, B.S. and Joyce, J.N. Neonatal 6-OHDA lesions lead toopposing changes in the levels of dopamine receptors and their mRNAs. Neuroscience,68:505-518, 1995.53. Frohna, P.A., Rothblat, D.S, Schneider, J.S. and Joyce, J.N. Alterations in dopamineuptake sites and D1 and D2 receptors in cats symptomatic for and recovered from13

Jeffrey N. Joyce, Ph.D. December 2012experimental parkinsonism. Synapse 19:46-55, 1995.54. Goldsmith, S. and Joyce, J.N. Alterations in the hippocampal mossy fiber pathway inschizophrenia and Alzheimer’s disease. Biol. Psychiatry 37:122-126, 1995.55. Murray, A.M., Weihmueller, F., Marshall, J.F. Hurtig H.I., Gottleib, G.L. and Joyce, J.N.Damage to dopamine systems differs between Parkinson’s Disease and Alzheimer’s withParkinsonism. Annal. Neurol. 37:300-312, 1995.56. Murray, A.M., Ryoo, H., Gurevich, E. and Joyce, J.N. Localization of dopamine D3receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain.Proc. Natl. Acad. Sci. USA 91:11271-11275, 1994.57. Lexow, N., Joyce, J.N., Kim, S.J., Phillips, J., Casanova, M.F., Bird, E.D., Kleinman,J.E.and Winokur, A. Alterations in TRH receptors in temporal lobe of schizophrenics: Aquantitative autoradiographic study. Synapse 18: 315-327, 1994.58. Ulas, J., Weihmuller, F.B., Brunner, L.C., Joyce, J.N., Marshall, J.F., and Cotman, C.W.:Selective increase of NMDA-sensitive glutamate binding in the striatum of Parkinson’sdiseae, Alzheimer’s disease, and mixed Parkinson’s disease/Alzheimer’s disease patients:an autoradiographic study. J. Neurosci. 14:6317-6324, 1994.59. Ryoo, H and Joyce, J.N. The loss of dopamine D2 receptors varies along the rostrocaudalaxis of the hippocampal complex in Alzheimer’s disease. J. Comp. Neurol. 348:94-110,1994.60. Goldsmith, S. and Joyce, J.N. D2 receptor expression in hippocampus andparahippocampal cortices of human, rat and cat in comparison with tyrosine hydroxylaseimmunoreactive fibers. Hippocampus 4:1-20, 1994.61. Rioux, L., Neal, B.S. and Joyce, J.N. Substance P receptors are differentially altered inParkinson's and Alzheimer's disease. J. Neural Transm.-Parkinson's Dis DementiaSection. 6: 199-210, 1993.62. Neal-Beliveau, B.S. and Joyce, J.N. D1 and D2 dopamine receptors do not up-regulate inresponse to neonatal intrastriatal 6-hydroxydopamine lesions. Neurosci. Lett. 160:77-80,1993.63. Frohna, P.A., Neal-Beliveu, B.S. and Joyce, J.N. Neonatal 6-OHDA lesions upregulateadult expression of tyrosine hydroxylase mRNA. NeuroReport 4: 1095-1098, 1993.64. Neal-Beliveau, B.S., Joyce, J.N., and Lucki, I. Serotonergic involvement in haloperidolinducedcatalepsy. J. Pharmacol. Expt. Therap. 265: 207-217, 1993.65. Joyce, J.N., Kaeger, C, Ryoo, H and Goldsmith, S.: Dopamine D2 receptors in thehippocampus and amygdala in Alzheimer’s disease. Neurosci. Lett..154:171-174, 1993.66. Joyce, J.N., Shane, A., Lexow, N., Winokur, A., Casanova, M. F., and Kleinman, J. E.:Serotonin uptake sites and serotonin receptors are altered in limbic system ofschizophrenics. Neuropsychopharmacol. 8:315-336, 1993.67. Joyce, J.N. Differential response of striatal dopamine receptor subtypes and cholinergic14

Jeffrey N. Joyce, Ph.D. December 2012muscarinic receptors to the loss of dopamine: III. Effects in Parkinson’s disease. BrainRes.600:156-160, 1993.68. Murray, A.M., Roo, H., and Joyce, J. Visualization of dopamine D3-like receptors inhuman brain with [ 125 I]epidepride. Eur. J. Pharmacol. Mol. Pharmacol. Sect. 227:443-445, 1992.69. Neal, B.S. and Joyce, J.N. Neonatal 6-hydroxydopamine lesions differentially affectstriatal D1 and D2 receptors. Synapse 11:35-46, 1992.70. Joyce, J.N., Lexow, N., Kim, S.J., Artymysh, R., Cassanova, M., Kleinman, J., E. Bird,and A. Winokur.: Distribution of Beta-adrenergic receptor subtypes in human postmortembrain: alterations in limbic regions of schizophrenics. Synapse 10:228-246, 1992.71. Joyce, J.N. Differential response of striatal dopamine receptor subtypes and cholinergicmuscarinic receptors to the loss of dopamine: II. Effects of 6-hydroxydopamine orcolchicine microinjections in the VTA or reserpine treatment. Exp. Neurol. 113:277-290,1991.72. Joyce, J.N. Differential response of striatal dopamine receptor subtypes and cholinergicmuscarinic receptors to the loss of dopamine: I. Effects of intranigral orintracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system.Exp. Neurol. 113:261-276, 1991.73. Neal, B.S. and Joyce, J.N. Dopamine D1 receptor behavioral supersensitivity followingselective lesions of the striatal patch compartment during development. Dev. Brain Res.60:105-113, 1991.74. Rao, P., Molinoff, P.B. and Joyce, J.N. Ontogeny of dopamine D1 and D2 receptorsubtypes in rat basal ganglia: a quantitative autoradiographic study. Dev. Brain Res.60:161-177, 1991.75. Joyce, J.N., Janowski, A. and Neve, K.A. Characterization and distribution of[ 125 I]Epidepride binding to dopamine D2 receptors in basal ganglia and cortex of humanbrain. J. Pharmacol. Exp. Ther. 257:1253-1263, 1991.76. Lowenstein, P.R., Joyce, J.N., Coyle, J.T., and Marshall, J.F. Striosomal organization ofcholinergic and dopaminergic uptake sites and cholinergic M1 receptors in the adulthuman striatum: A quantitative receptor autoradiographic study. Brain Res.510:122-126,1990.77. Marshall, J.F., Navarrete, R. and Joyce, J.N. Decreased striatal D1 binding densityfollowing mesotelencephalic 6-hydroxydopamine injections: An autoradiographicanalysis. Brain Res. 493: 247-257, 1990.78. Joyce, J.N., Gibbs, R.B., Cotman, C.W. and Marshall, J.F. Regulation of muscarinicreceptors in hippocampus following cholinergic denervation and reinnervation by septaland striatal transplants. J. Neuroscience 9: 2776-2791, 1989.79. Hurtig, H., Joyce, J.N., Sladek, J.R., and Trojanowski, J. Post mortem analysis ofautograft from adrenal medulla to caudate in a patient with Parkinson's disease. Annal.15

Jeffrey N. Joyce, Ph.D. December 2012Neurol. 25:607-614, 1989.80. Joyce, J.N., Lexow, N., Bird, E. and Winokur, A. Organization of dopamine D1 and D2receptors in human striatum: receptor autoradiographic studies in Huntington's diseaseand schizophrenia. Synapse 2: 546-557, 1988.81. Rhodes, K.J., Joyce, J.N., Sapp, D.W. and Marshall, J.F. [ 3 H]Hemicholinium-3 bindingin rabbit striatum: correspondence with patchy acetylcholinesterase staining and a methodfor quantifying striatal compartments. Brain Res. 412:400-404, 1987.82. Joyce, J.N. and Marshall, J.F. Quantitative autoradiography of dopamine D-2 sites in ratcaudate-putamen: Evidence for localization to intrinsic neurons and not to neocorticalafferents. Neuroscience 20:773-795, 198783. Joyce, J.N., Sapp, D.W. and Marshall, J.F.: Human striatal dopamine receptors areorganized in patches. Proc. Natl. Acad. Sci. U.S.A. 83:8002-8006, 1986.84. Joyce, J.N., Marshall, J.F., Bankiewicz, K.S., Kopin, I.J. and Jacobowitz, D.M.:Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regionalipsilateral changes in striatal dopamine D 2 receptor density. Brain Res. 382:360-364,1986.85. Van Hartesveldt, C. and Joyce, J.N. Effects of estrogen on the basal ganglia. Neurosci.Biobehav. Rev.10:1-14, 1986.86. Joyce, J.N., Loeschen, S.L., Sapp, D.W. and Marshall, J.F. Age-related regional loss ofcaudate-putamen dopamine receptors revealed by quantitative autoradiography. BrainRes. 378:158-163, 1986.87. Joyce, J.N., Loeschen, S. and Marshall, J.F. Dopamine D-2 receptors in rat caudateputamen:The lateral to medial gradient does not correspond to dopaminergic innervation.Brain Res. 338:209-218, 1985.88. Joyce, J.N. and Marshall, J.F. Striatal topography of D-2 receptors correlates withindexes of cholinergic neuron localization. Neurosci. Lett. 53:127-131, 1985.89. Rowland, N., Joyce, J.N. and Bellush, L.L. Stereotyped behavior and diabetes mellitusin rats: Reduced behavioral effects of amphetamine and apomorphine and reduced in vivobrain binding of 3H-spiroperidol. Behav. Neurosci. 99:831-841, 1985.90. Joyce, J.N. and Van Hartesveldt, C. Rotation and postural deviation elicited bymicroinjections of dopamine into medial and lateral regions of dorsal striatum.Pharmacol. Biochem. Behav. 21:979-981, 1984.91. Joyce, J.N., Montero, E. and Van Hartesveldt, C. Dopamine-mediated behaviors:Characteristics of modulation by estrogen. Pharmacol. Biochem. Behav. 21:791-800,1984.92. Joyce, J.N. and Van Hartesveldt, C. Estradiol application to one striatum producespostural deviation to systemic apomorphine. Pharmacol. Biochem. Behav. 20:575-581,16

Jeffrey N. Joyce, Ph.D. December 20121984.93. Joyce, J.N. and Van Hartesveldt, C. Behaviors induced by intrastriatal dopamine varyindependently across the estrous cycle. Pharmacol. Biochem. Behav. 20:551-557, 1984.94. Joyce, J.N., Smith, R.L. and Van Hartesveldt, C. Estrogen enhances then suppressesintracaudate dopamine-induced contralateral deviation. Eur. J. Pharmacol. 81:117-122,1982.95. Joyce, J.N., Davis, R.E. and Van Hartesveldt, C.: Systemic apomorphine reverseintrastriatal dopamine-induced contralateral deviation. Eur. J. Pharmacol. 87:283-289,1983.96. Joyce, J.N., Davis, R.E. and Van Hartesveldt, C.: Behavioral effects of unilateraldopamine injection into dorsal or ventral striatum. Eur. J. Pharmacol. 72:1-10, 1981.Editorials, Reviews, Chapters1. Joyce, J.N. and Millan, M.J. Dopamine D3 receptor agonists for protection and repair inParkinson's disease. Current Opinion in Pharmacology 2007, 7:100–105.2. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation inAlzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?Int Rev Neurobiol. 2007;82:235-463. Joyce, J.N. and Millan, M.J. Dopamine D 3 receptor antagonists as therapeutic agents.Drug Discov Today. 2005 10(13):917-25.4. Joyce, J.N. (2001) Dopamine D 3 receptor as a therapeutic target for antipsychotic andantiparkinsonian Drugs. Pharmacology & Therapeutics 90(2-3):231-259.5. Joyce, J.N. Chapter 48: The Basal Ganglia Dopaminergic Systems in Normal Aging andParkinson’s Disease. In : Functional Neurobiology of Aging, P.R. Hof and C.V. Mobbs(Eds), pp 689-709, Academic Press, San Diego, 2001.6. Joyce, J. N., Ryoo, H., Gurevich, E. V., Adler, C., and Beach, T. (2001) Ventral striatalD 3 receptors and Parkinson's Disease. Parkinsonism Related Dis. 7(3):225-230.7. Joyce, J.N. and Gurevich, E.V. D 3 receptors and the actions of neuroleptics in the ventralstriatopallidal system of schizophrenics, Advancing from the Ventral Striatum to theExtended Amygdala: Implications for Neuropsychiatry and Drug Abuse, M.F. McGinty,(Ed), Annals of the New York Academy of Science , 877: 595-614, 1999.8. Joyce, J.N. and Gurevich, E.V. The dopamine D 3 receptor: From neuroanatomy toneuropsychiatry, NeuroScience News, 2:11-21, 1999.9. Joyce, J.N. and Meador-Wooodruff, J.H. Linking the family of D2 receptors to neuronalcircuits in human brain: insights into schizophrenia. Neuropsychopharmacol. 16:375-384,1997.10. Joyce, J.N., and A. Murray: Chapter 16: Distribution of D1 and D2-like dopaminereceptors in human brain. In: Dopamine Receptors and Transporters, Hyman B. Niznik17

Jeffrey N. Joyce, Ph.D. December 2012(Ed),PP 345-382, Marcel Dekker, Inc., New York, 1994.11. Joyce, J.N., S. G. Goldsmith and E. V. Gurevich. Limbic circuits and monoaminereceptors: dissecting the effects of antipsychotics from disease processes. J. PsychiatryRes.31:197-217, 1997.12. Joyce, J.N., Frohna, P.S. and Neal-Beliveau, B.S. Functional and moleculardifferentiation of the dopamine system induced by neonatal denervation. Neurosci.Biobehav. Rev. 20: 453-486, 1997.13. Joyce, J.N., and Neal-Beliveau, B.S. Developmental plasticity of dopamine systems:preandpostsynaptic components of the dopamine system are modified by neonatal lesions.In: The Basal Ganglia IV. New Ideas and Data on Structure and Function , G. Percheron,J.S.McKenzie andJ. Féger (Eds), PP 137-148, Plenum Press, Inc., London, 1994.14. Joyce, J.N. and Hurtig, H.I. Neurodegenerative Disorders. In: Biological Bases of BrainFunction and Disease, Chapter 23, A. Frazer, P.Molinoff and A. Winokur (Eds), PP 425-448, Raven Press, New York, 1993.15. Joyce, J.N., Goldsmith, S., and Murray, A. Neuroanatomical localization of D-1 vs D-2receptors: similar organization in the basal ganglia of the rat, cat and human and disparateorganization in the cortex and limbic system. In: Dopamine Receptor Interactions,Chapter 2, J.L. Waddington (Ed), PP 23-49, Academic Press Limited, Harcourt BraceJovanovich, 1993.16. Joyce, J.N. The dopamine hypothesis of schizophrenia: limbic interactions withserotonin and norepinephrine. Psychopharmacology 112:S16-S34, 1993.17. Joyce, J.N., Emerich, D. F., Norman, A. B., and Sanberg, P.R. Regulation andassessment of receptors following transplants. Chapter 30, In: Methods in Neurosciences,Volume 7, ed. P. M. Conn, Academic Press, San Diego, CA, PP 456-477, 1991.18. Joyce, J.N., Hensler, J.G., and Tejani-Butt, S.M. Neurochemical lesioning techniques forassessing regulation of monoamine receptors. Chapter 16, In: Methods in Neurosciences,Volume 7, ed. P. M. Conn, Academic Press, San Diego, CA, PP. 216-240, 1991.19. Joyce, J.N. and Hurtig, H. Differential regulation of dopamine D1 and D2 receptorsystems in Parkinson's disease and effects of adrenal medullary transplant. In: NeuralTransplantation: From Molecular Basis to Clinical Application, Prog. Brain Res. 82:699-706, 1990.20. Joyce, J.N., Lexow, N., Neal, B., Hurtig, H., Trojanowski, J.Q. and Winokur, A.Receptor autoradiographic studies in neurodegenerative disorders of the basal ganglia. In:Neural Mechanisms in Disorders of Movement, eds A.R. Crossman and M.A. Sambrook,John Libbey & Company, PP 303-312, 1989.21. Joyce, J.N., Gibbs, R.B., Cotman, C.W. and Marshall, J.F. Chapter 14. Regulation ofacetylcholine muscarinic receptors by embryonic septal grafts showing cholinergicinnervation of host hippocampus. Gash, D.M. and J.R. Sladek (eds). Prog. Brain Res.,78:109-116, 1988.18

Jeffrey N. Joyce, Ph.D. December 201222. Marshall, J.F. and Joyce, J.N. Basal ganglia dopamine receptor autoradiography and agerelatedmovement disorder. In: Central Determinants of Age-Related Declines in MotorFunction. edited by J. Joseph, PP 215-225, 1988.23. Altar, C.A., Joyce, J.N. and Marshall, J.F. Functional organization of dopamine andserotonin receptors in the rat forebrain. In: Quantitative Receptor Autoradiography,Boast, C.A., Snowhill, E. and Altar, C.A., eds. Alan R. Liss: New York, New York,pp.53-78, 1986.24. Joyce, J.N. Multiple dopamine receptors and behavior. Neurosci. Biobehav. Rev. 7:227-256,1983.PREVIOUS RESEARCH SUPPORTFederal1RO1 DA13649-03 (Neisewander) 1/30/2004- 6/30/2007 10%NIDA$225,000 (subcontract)Limbic-cortical involvement in drug-seeking. Subcontract:Gene expression profiling ofcocaine’s effects5R01 NS40699 (Joyce) 7/1/00 to 6/30/03 25%NINDS $1,129,533Mesolimbic Dopamine D3 Receptor and Parkinson’s Disease5PO1 AG09215 (Trojanowski) 5/1/96 - 4/30/03 25%NIA $945,000Molecular Substrates of Aging and Neuron Death, Project 1: Degeneration of DopaminergicPathways5R01 MH 56824-01 (Joyce)NIMHMesolimbic DA D3 Receptor and Schizophrenia5R01 MH 48813-01A2 (Joyce)NIMHDevelopmental Plasticity of Dopamine Systems7/1/96 - 6/30/99$523,6177/1/93 - 6/31/96$350,00025%25%P5O MH 43880 (Gur)7/1/91 - 6/30/96 25%NIMHRegional Brain Function in Schizophrenia Core VI. Neuropharmacology5PO1 NS 08803 (Gennarelli) 4/01-91 - 3/31/94 10%NINDSHead Injury Clinical Research Center: Project 1: Receptor Changes in Human Head Injury1-S15-MH-49277-01ADAMHA Small Instrumentation GrantAwarded for purchase of Reichert Jung Cryostat.9/30/91-8/30/92$18,22119

Jeffrey N. Joyce, Ph.D. December 20125R29 MH 48352 (Joyce) 5/1/88 - 4/31/93 50%NIMH $542,500Neurotransmitter disorders in schizophrenia5P01GM034781 (Molinoff) 4/1/86-3/31/90 25%NIGMS$212,000Pharmacology of Receptor/Effector Systems, Project 5: Regulation of dopamine recep torsStateABRC Center Project contract number 0011 (Adler) 10/1/2005 – 6/30/2008 25%Arizona Biomedical Research Commission$150,000Prevention of Progression to Parkinson’s Disease and P rkinson’s Disease with Demen tia:Development of Biomarkers and Treatment Strategies: P roject 1 (Joyce): “Deficient L evels ofBDNF in Cortical Neurons of Parkinson’s Disease with Dementia”.ADRC contract 4001 (Joyce)9/1/01 – 6/30/04 25%Arizona Disease Control Research Commission$550,000Arizona Parkinson’s Disease CenterFunding for 4 projects (subcontracts) and Core (Brain Donor Program) in Parkinson’s diseaseState of Arizona AZDHS (Reiman) 7/1/98-6/31/02 5%Arizona Alzheimer’s Disease Research Center $360,000Subproject: Antemortem and postmortem differentiation of Lewy body diseaseFoundationMJF for Parkinson’s Research fast track grant (Joyce) 3/01/03 - 2/28/04 15% TheMichael J. Fox Foundation for Parkinson’s Research $50,000DA agonist neuroprotection via Akt pathway in MPTP mouse model of ParkinsonsScottish Rite Schizophrenia Research Program (Joyce) 9/01/96 - 8/30/98 15%THE SUPREME COUNCIL 33°, SCOTTISH RITE $75,000Disturbed patterns of D2 receptor mRNA expressing neurons in the temporal lobe ofschizophrenicsScottish Rite Schizophrenia Research Program (Joyce)THE SUPREME COUNCIL 33°, SCOTTISH RITELimbic Dopamine Receptors8/1/93 - 7/30/95$75,00015%Scottish Rite Schizophrenia Research Program (Joyce) 8/1/87 - 7/31/8915%THE SUPREME COUNCIL 33°, SCOTTISH RITE $40,000Visualization of Neurochemical and Neuropathological Changes in Post Mortem SchizophrenicTissue Utilizing Neurotransmitter Autoradiography20

Jeffrey N. Joyce, Ph.D. December 2012AFAR Junior Faculty Research Award (Joyce) 7/1/87 - 6/30/88 15%American Federation for Aging Research $35,000Neurotransmitter Alterations in Aged StriatumIndustry-PharmaceuticalInstitute de Recherches Servier (Joyce)4/31/04 - 9/30/0415%Institute de Recherches Servier, France$76,800Neuroprotective effects of S38646 as compared to reference compounds in Parkinsonian models.Institute de Recherches Servier (Joyce) 1/315/01 to 9/30/02 10%Institute de Recherches Servier, France $76,800Neuroprotective effects of S32504 as compared to reference compounds in Parkinsonian models.RW Johnson PRI (Joyce) 9/01/02 – 3/31/03 10%RW Johnson PRI (New Jersey) $60,000Neuroprotection afforded by topiramate in models of ParkinsonsPharmacia Corporation (Joyce) 12/11/98 - 3/30/01 10%Pharmacia Corporation, Kalamazoo MI $45,000Effects of pramipexole on cell death using the neuroblastoma cell line SH-SY5Y in response toMPP+Pharmacia & Upjohn (Joyce) 1/01/97 - 3/30/98 10%Pharmacia Corporation, Kalamazoo MI $45,000[3H]Pramepixole binding to D3 receptors in human brainSmithKline Beechum (Joyce) 3/1/93 - 12/31/94 10%SmithKline Beechum, United Kingdom (GlaxoSmithKline) $75,000[ 3 H]Paroxetine binding to human brainPfizer Central Research (Joyce) 7/01/90 - 6/30/91 10%Pfizer Central Research, Groton CT $45,000Distribution of [ 3 H]CP96,345 binding in post-mortem human brain- A substance P receptorantagonistE.R. SQUIBB & Sons Pharmaceuticals (Joyce) 11/30/90 - 11/30/91 10%E.R. SQUIBB & Sons Pharmaceuticals, Princeton, New Jersey (Bristol-Myers Squibb)Central nervous system distribution, pharmacology and regional effects of SQ29852Lectures by Invitation (1992-2006)January 10, 1992, "Age dependence of the neurochemical and behavioral effects of damageto the dopamine system," Invited Speaker, Winter Conference on DevelopmentalPsychobiology, Cancun, Mexico.21

Jeffrey N. Joyce, Ph.D. December 2012February 17, 1992, "Developmental dopamine plasticity, "Invited Speaker, Department ofPharmacology, Medical College of Pennsylvania, Philadelphia, PA.February 25, 1992, "Monoamine receptors, limbic pathology and schizophrenia,"Invited Speaker, Neuroscience Program Seminar Series, University ofIllinois, Urbana-Champaign, ILMay 6, 1992, "Monoamines, limbic pathology and schizophrenia,", Invited Speaker, Symposia"Dopamine and Serotonin Interactions in Schizophrenia," American PsychiatricAssociation 14Sth Annual Meeting, Washington, D.C.May 24, 1992, "Developmental Plasticity of Dopamine Systems," Invited Speaker,7th International Catecholamine Symposium, Amsterdam, The NetherlandsJune 29, 1992, "Monoamine receptors, limbic pathology and schizophrenia,", InvitedSpeaker, Symposia "New Neuropathological Findings in Schizophrenia,"Collegium Internationale NeuroPsychopharmacologicum XVIIIth Annual Meeting,Nice.September 23, 1992, "The role of dopamine in receptor expression differs in the neonate and theadult," Invited Speaker, Department of Pharmacology, Temple University, Philadelphia,PA.October 5, 1992, "Damage to the early developing dopamine system permanently alters thematrix-directed dopamine system," Invited Speaker, International Basal GangliaSociety Meetings, Giens-Hymeres, FranceOctober 13, 1992, "Developmental plasticity of the dopamine system: role of dopamine as aneurotrophin," Invited Speaker, Junior Faculty Scholars Program, The RockefellerUniversity, New York, N.Y.November 16, 1992, "An anatomical basis for monoamine interactions in schizophrenia,"Invited Speaker, Department of Psychiatry, Mount Sinai School of Medicine, NewYork.December 18, 1992, "Characterization of the binding of [125I]epidepride and [125I]NCQ 298binding to D2 and D3-like dopamine receptors in human brain," Panel "PET Studies ofDopamine Function, American College of Neuropsychopharmcology Annual Meeting,San Juan, Puerto Rico.January 24, 1993, "Therapeutics of Parkinson's disease: new insights into oldquestions," Workshop, Twenty-Sixth Annual Winter Conference on BrainResearch, Whistler, BC, Canada.May 27, 1993, "Psychosis, Dementia and the Medial Temporal Lobe, " Symposium Chair,146th Annual Meeting, American Psychiatric Association, San Francisco,California ..December 16, 1993, "Anatomy of the 5-HTIA receptor and 5-HT transporter ([125IRTI-55and [3H]paroxetine) in human brain: alterations in schizophrenia, Panel: 5-HT lAreceptor: molecular regualtion, endocrine control and schizophrenia, AmericanCollege of Neuropsychopharmacology, 32nd Annual Meeting, Honolulu, Hawaii.April 8, 1994, "Novel Dopamine Receptors: Alterations in Alzheimer's Disease," InvitedSpeaker, Sun Health Research Center, Sun City, AZ.April 13, 1994, "Novel Dopamine Systems in Human Brain: Implications for UnderstandingSchizophrenia," Invited Speaker, UpJohn Pharmaceuticals, Kalamazoo, MI.22

Jeffrey N. Joyce, Ph.D. December 2012May 2, 1994, "Meso striatal and Mesolimbic Dopamine Systems in NeurodegenerativeDisorders," Invited Speaker, Department of Pharmacology, Texas Tech UniversityHealth Sci Ctr, Lubbock, TX.June 1, 1994,"Nove1 Dopamine Systems in Human Brain: Implications for UnderstandingNeuropsychiatric and Neurodegenerative Disorders," Invited Speaker, Department ofRadiology, Bringham and Women's Hospital, Harvard Univeristy, Boston MA.June 24, 1994, "Dopamine D2 and D3 receptors are altered in schizophrenia: Implications fortreatment," Division of Molecular Biology and Division of Central Nervous SystemGoint sponsor), WyethAyerst Pharmaceuticals, Princeton, N.J.July 6, 1994,"Schizophrenia and monaminergic systems: postmortem studies implicateconvergent effects in ventral striatum and divergent effets in medial temporal lobe,"Invited Speaker, Department of Psychiatry, Mailman Research Center, McLeanHospital, Harvard Univeristy, Boston MA.July 30, 1994, "Anatomy of novel dopamine receptors in human brain and their alterations inschizophrenia," Western Psychiatric Institute and Clinic, University of PittsburghMedical Center, Pittsburgh, PA.September 7, 1994, "Developmental sequalae of the mesostriatal dopamine system andalterations by dopamine depletion," Invited Speaker, Department ofNeuroscience, University of Pittsburgh, Pittsburgh, PA.October 12, 1994, "Novel dopamine receptors and their role in schizophrenia," GrandRounds Invited Speaker, Department of Psychiatry, Wayne State University,Detroit, MI.December 14, 1994, "Dopamine D3 receptors labeled with [125I]trans-7-0H-PIPAT areelevated in schizophrenic brain and decreased by neuroleptic treatment. Panel:Thenew dopamine receptors: Is there something new in the neuropathology ofschizophrenia? D3-D5 receptors, American College ofNeuropsychopharmacology, 33rd Annual Meeting, San Juan, Puerto Rico.April 7, 1995, "Differential loss of dopamine transporter and tyrosine hydroxylase rn.RNAs inmidbrain of Parkinson's, Alzheimer with parkinsonism and Alzheimer's disease.Invited participant, Neurodegenerative Disorders: Common Molecular Mechanisms,Ocho Rios, Jamaica.December 13, 1995, Panel Chair: Dopamine D3 receptors: From Molecules to Medicine.American College of Neuropsychopharmacology, 34th Annual Meeting, San Juan,Puerto Rico.May 15, 1996, "Parkinsonian Symptoms in Alzheimer's Disease: A Different Neuropathology,"Department of Neurology, Rush-Presbytarian, Chicago Illinois.April 16, 1997, “Prefrontal cortex serotonin and the mesolimbic dopamine system: sites forantipsychotic action,” Wyeth-Ayerst Pharmaceutical, CNS Division, Princeton NJ.May 17, 1997, “Prefrontal cortex and serotonin in schizophrenia: effects of antipsychotictreatment,” Ziskind-Somerfeld Research Awardee, Society for Biological Psychiatry1997 Annual Meeting, San Diego, CA.June 19, 1997, “Dopamine receptors in human brain,” Invited speaker, XVIIIth International23

Jeffrey N. Joyce, Ph.D. December 2012Symposium on Cerebral Glood Flow & Metabolism, Baltimore MD.April 21, 1998, “Dopamine D3 receptor as a target of antipsychotics, “ Invited speaker,Neurosciences Program, University of Michigan, Ann Arbor, MI.July 16, 1998, “Molecular substrates of neurochemical disturbances in schizophrenia, “Symposium Chair, XXI CINP Congress, Glasgow Scotland.July 21, 1998, “Extrapyramidal symptoms in Alzheimer’s disease: Underlying mechanisms,”Invited Speaker, Molecular and Cellular Biology Lecture Series, University ofManchester, Manchester EnglandJuly 25, 1998, “Dopamine D3 receptors: Ontogeny and alterations in schizophrenia,” InvitedSpeaker, DA ’98, Strasbourg France.September 28, 1998, “Extrapyramidal symptoms in Alzheimer’s disease: Underlyingmechanisms,” Invited Speaker, Molecular and Cellular Biology Lecture Series, ArizonaState University, Tempe AZOctober 18-21, 1998, “D 3 receptors and the actions of neuroleptics in the ventral striatopallidalsystem of schizophrenics,” Invited Speaker, New York Academy of SciencesConference, Advancing From the Ventral Striatum to the Extended Amygdala:Implications for Neuropsychiatry and Drug Abuse, Charlottesville, VirginiaOctober 31- November 4, 1998, “Segregation and co-expression of D 2 and D 3 receptors in thebrain of schizophrenic patients: postmortem studies,” Invited Speaker, Symposia: TheDopamine Hypothesis of Schizophrenia Revisited, European College ofNeuropschopharmacology, Paris, FranceMarch 16, 1999, “The dopamine D 3 receptor: from neuroanatomy to neuropsychiatry.” InvitedSpeaker, The Department of Pharmacology, The University of Texas Health SciencenCenter at San Antonio. San Antonio Texas.October 22, 1999, “Distribution and regulation of D 3 receptors in Parkinon’s Disease.” InvitedSpeaker, 6 th National Parkinson Foundation International Symposium on Parkinson’sResearch, Miami Florida, USA.January 11, 2000, “The dopamine D 3 receptor from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, The Parkinson’s Institute, Sunnvale CA, USA.May 12, 2000, “The dopamine D 3 receptor from neuroanatomy to potential target forantipsychotic drugs.” Invited Speaker, Workshop: Schizophrenia: Pathological Bases andMechanisms of Antipsychotic Action, Organized by Institute de RecherchesInternationales Servier, Chicago IL.May 19, 2000, The dopamine D 3 receptor: from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, Unité de Recherche en Neuroscience, Centerede Recherche, Center Hospitalier Universitaire due Québec, Québec Canada.24

Jeffrey N. Joyce, Ph.D. December 2012May 31, 2000, The dopamine D 3 receptor: from neuroanatomy to potential target forantiparkinsonian drugs.” Invited Speaker, Rush University, Department of Pharmacology,Chicago IL.April 25, 2001, The dopamine D 3 receptor as a therapeutic target for antiparkinsonian drugs.”Invited Speaker, University of Tennessee, Department of Pharmacology, Memphis, TN.April 30, 2001, “Neuroprotection by Antiparkinsonian Drugs: basic and clinical research.”Invited Speaker, Cellular and Molecular Biology Series, Arizona State University, TempeAZ.April 12, 2002, “The dopamine D 3 receptor as a therapeutic target for antipsychotic drugs.”Invited Speaker, Pfizer Pharmaceuticals, Groton CT.May 1, 2002, “Neuroprotection by D 3 preferring agonists: basic and clinical research.” InvitedSpeaker, Pharmacology Department, University of San Antonio, San Antonio TX.September 18, 2002, “Neuroprotective properties of pramipexole in vitro and in vivo.” InvitedSpeaker, Pharmacology Department, Pharmacia Corporation, Kalamazoo MI.September 24, 2002,” Neuroprotective properties of D3 agonists in vitro and in vivo.” InvitedSpeaker, Pharmacology Department, University of North Texas Health Science Center atFort Worth, Fort worth TX.February 27-28, 2003, “Dopamine D3 partial agonists as therapeutic target in PD.” InvitedParticipant, Expert Workshop in Therapeutic Targets for Treatment of Parkinson'sDisease and Related Disorders, New York, NY, SCHWARZ Biosciences.August 7, 2003, “Mechanisms of neuroprotection for D3 agonists in Parkinson’s disease.”Invited Speaker, The Parkinson’s Disease Task Force, University of California at Irvine,Irvine CA.September 18, 2003, “Mechanisms of neuroprotection for D3 agonists in Parkinson’s disease.”Invited Speaker, Intitut de Recherches Servier, Suresnes, FranceSeptember 24, 2003, Chair, Interface track, “The dopamine D3 receptor and its ligands:Therapeutic implications.” 16 th European College of NeuropsychopharmacologyCongress, Prague, Czech Republic.March 25, 2004, , “Mechanisms of neuroprotection for D3 agonists in Parkinson’s disease.”Invited Speaker, Eli Lilly and Company, Indianapolis, IN.May 3, 2004, “Mechanisms of Neuroprotection Using Antiparkinsonian Agents.” InvitedSpeaker, Wyeth Research, Princeton, NJ.May 11, 2004, "Mechanisms of cell death by toxins in terminally differentiated SH-SY5Y cellsand neuroprotection by dopamine agonists." Invited Speaker, Barrow Neurologic InstituteNeuroscience Conference, Phoenix, AZ.25

Jeffrey N. Joyce, Ph.D. December 2012December 14, 2004, Chair, Panel: “Therapeutic role of D3 receptor drugs in schizophrenia,neuroprotection, and drug addiction.” The 43rd ACNP Annual Meeting, Caribe Hilton inSan Juan, Puerto Rico.December 14, 2004, Panel Speaker “D3 receptor-mediated intracellular pathways forneuroprotection against the Parkinson toxin 1-methyl-4-phenylpyridinium (MPP+).” The43rd ACNP Annual Meeting, Caribe Hilton in San Juan, Puerto Rico.February 23, 2005, Mechanisms of Neuroprotection by Dopamine Agonists in Parkinson’sDisease” Cellular and Molecular Pharmacology Rosalind Franklin University ofMedicine & Science, North Chicago, ILMay 3, 2005, “Can we slow down the progression of Parkinson’s Disease?”, CME GrandRounds, Sun Health /St Joseph’s Geriatric Fellowship Program, Boswell Hospital, SunCity, AZ.September 26, 2005 “DNA damage and cell death in PD”. Oklahoma Medical ResearchFoundation, Oklahoma City, OklahomaNovember 11, 2005 “Mechanisms of Neuroprotection by Dopamine Agonists in Parkinson’sDisease” Neurotoxicity Society Satellite Meeting Dopamine Oxidation and Parkinson´sdisease, Washington, D.C.May 13, 2006. Invited Speaker, “DA neuron death initiated by DNA damage and protection byD3 preferring agonists” Plasticity and Repair in Neurodegenerative Disorders Workshop,UCLA Conference Center , Lake Arrowhead, California, May 11- 14, 2006December 15, 2006. Invited Speaker, “Loss of clinical response to antiparkinsonian drugs(APDs) and the DA D 3 receptor. “ Grand Rounds, Department of Neurology, Universityof Arizona Medical Center, Tucson AZ26